3-哌啶-3-基-1H-吡咯并[2,3-B]吡啶 | 1001069-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 3-哌啶-3-基-1H-吡咯并[2,3-B]吡啶
• 英文名称: 3-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 3-Piperidin-3-yl-1h-pyrrolo[2,3-b]pyridine
• CAS: 1001069-39-1
• 化学式: C₁₂H₁₅N₃
• 分子量: 201.271
• InChiKey: NDEZQKHXMUBWSL-UHFFFAOYSA-N

物化性质

• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-哌啶-3-基-1H-吡咯并[2,3-B]吡啶 在 sodium hydride 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-(1-(4-(benzo[b]thiophen-2-yl)pyrimidin-2-yl)piperidin-3-yl)-1-methyl-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors

  摘要：

  Starting from a series of ureas that were determined to be mechanism-based inhibitors of FAAH, several spirocyclic ureas and lactams were designed and synthesized. These efforts identified a series of novel, noncovalent FAAH inhibitors with in vitro potency comparable to known covalent FAAH inhibitors. The mechanism of action for these compounds was determined through a combination of SAR and co-crystallography with rat FAAH. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.052
• 作为产物：
  描述：

  N-叔丁氧羰基-3-哌啶酮 在 20 % Pd(OH)2/C 、 氢气 、 sodium methylate 、 三氟乙酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 80.0 ℃ 、344.75 kPa 条件下， 生成 3-哌啶-3-基-1H-吡咯并[2,3-B]吡啶
  参考文献：
  名称：

  Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors

  摘要：

  Starting from a series of ureas that were determined to be mechanism-based inhibitors of FAAH, several spirocyclic ureas and lactams were designed and synthesized. These efforts identified a series of novel, noncovalent FAAH inhibitors with in vitro potency comparable to known covalent FAAH inhibitors. The mechanism of action for these compounds was determined through a combination of SAR and co-crystallography with rat FAAH. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.052

文献信息

• AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION
  申请人：STOIT Axel

  公开号：US20080009514A1

  公开（公告）日：2008-01-10

  Azaindole derivatives of formula (I): wherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, for example, their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors

  阿扎因多ール衍生物的公式（I）如下： 其中符号的含义如说明书中所给。这些化合物具有部分尼古丁乙酰胆碱受体激动作用和去甲肾上腺素再摄取抑制作用。本发明还涉及包含这些化合物的药物组合物，制造它们的方法，制造用于其合成的新的中间体的方法，制造组合物的方法以及这些化合物和组合物的用途，例如，用于将它们施用于患者以在尼古丁受体和/或去甲肾上腺素转运体涉及的疾病中实现治疗效果，或者可以通过操纵这些受体来治疗的疾病。
• [EN] SELECTIVE AGONISTS OF 5-HT2A RECEPTOR AND METHODS OF USE<br/>[FR] AGONISTES SÉLECTIFS DU RÉCEPTEUR 5-HT2A ET PROCÉDÉS D'UTILISATION
  申请人：UNIV YALE

  公开号：WO2022067165A1

  公开（公告）日：2022-03-31

  The present disclosure describes in one aspect tetrahydropyridine compounds of formula (I), which are 5-HT2A receptor agonists that exhibit selective binding to the 5-HT2A receptor over the 5-HT2B receptor. In certain embodiments, the compound of formula (I) is a compound of formula (II). Also provided herein are methods of treating, ameliorating, and/or preventing neurological diseases and disorders with compounds of formula (II).

  本公开描述了一种方面的四氢吡啶化合物的化学式(I)，这些化合物是5-HT2A受体激动剂，具有对5-HT2A受体的选择性结合，而不是对5-HT2B受体的结合。在某些实施例中，化合物的化学式(I)是化学式(II)的化合物。本文还提供了使用化学式(II)的化合物治疗、缓解和/或预防神经系统疾病和障碍的方法。
• [EN] 7-AZAINDOLE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS<br/>[FR] DÉRIVÉS 7-AZAINDOLE SERVANT D'INHIBITEURS SÉLECTIFS DE LA 11-BÉTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：MERCK PATENT GMBH

  公开号：WO2009059666A1

  公开（公告）日：2009-05-14

  The present invention relates to 7-azaindole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11 β-HSD-1 ) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

  本发明涉及式(I)的7-氮杂吲哚衍生物，作为选择性抑制酶11-β-羟基类固醇脱氢酶1（11 β-HSD-1）的药物，并且利用这些化合物治疗和预防代谢综合征、糖尿病、胰岛素抵抗、肥胖、脂质紊乱、青光眼、骨质疏松症、认知障碍、焦虑、抑郁、免疫紊乱、高血压以及其他疾病和病症。
• 7-Azaindole Derivatives as Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors
  申请人：Carniato Denis

  公开号：US20100267761A1

  公开（公告）日：2010-10-21

  The present invention relates to 7-azaindole derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

  本发明涉及式I的7-氮杂吲哚衍生物，作为11-β-羟基类固醇脱氢酶1型(11β-HSD-1)的选择性抑制剂，以及这种化合物在代谢综合症、糖尿病、胰岛素抵抗、肥胖症、脂质紊乱、青光眼、骨质疏松症、认知障碍、焦虑、抑郁、免疫障碍、高血压和其他疾病和情况的治疗和预防中的使用。
• Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
  申请人：Solvay Pharmaceuticals B.V.

  公开号：US08252930B2

  公开（公告）日：2012-08-28

  Azaindole derivatives of formula (I): wherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, for example, their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors.

  描述了式(I)的Azaindole衍生物，其中符号的含义在说明书中给出。这些化合物具有部分烟碱型乙酰胆碱受体激动和多巴胺再摄取抑制的组合作用。该发明还涉及含有这些化合物的制药组合物，制备它们的方法，用于合成其新型中间体的方法，制备组合物的方法以及这些化合物和组合物的用途，例如，将它们用于治疗涉及烟碱受体和/或多巴胺转运体的疾病，或可以通过操纵这些受体来治疗的疾病。